Thermo Fisher Scientific Inc., a global leader in scientific innovation, has officially opened its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia. This marks the company’s second ATxCC in the United States, following the launch of its Carlsbad, California facility. Together, these centers strengthen Thermo Fisher’s nationwide support network for cell and gene therapy (CGT) development, offering essential capabilities to biotech, biopharma, and translational researchers working on next-generation cell-based immunotherapies.
Advanced therapies continue to reshape modern medicine with the potential to treat — and in some cases cure — diseases once thought untreatable. With demand for these therapies rapidly increasing, the need for scalable and innovative development solutions has intensified. The new Philadelphia center underscores Thermo Fisher’s ongoing commitment to driving scientific breakthroughs and accelerating progress in healthcare.
The Philadelphia ATxCC is designed to help innovators navigate critical challenges in CGT development, supporting their journey from early research to clinical application and ultimately enabling faster delivery of transformative therapies to patients.
Situated within the newly expanded 53,000-square-foot BioLabs for Advanced Therapeutics Philadelphia incubator, the center gives emerging startups and established biopharma teams direct access to Thermo Fisher’s scientific expertise, advanced process development technologies, and collaborative opportunities.
By integrating the ATxCC into the BioLabs ecosystem, the partnership creates a highly accessible resource for founders and research teams working on breakthrough therapies in the region. The initiative opens the door to high-end technologies not only for BioLabs members but also for promising biotech companies across the East Coast and beyond.
Also Read